CY1122391T1 - Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια - Google Patents

Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια

Info

Publication number
CY1122391T1
CY1122391T1 CY20191100871T CY191100871T CY1122391T1 CY 1122391 T1 CY1122391 T1 CY 1122391T1 CY 20191100871 T CY20191100871 T CY 20191100871T CY 191100871 T CY191100871 T CY 191100871T CY 1122391 T1 CY1122391 T1 CY 1122391T1
Authority
CY
Cyprus
Prior art keywords
antibody
natural killer
subjects
kir2dl
pan
Prior art date
Application number
CY20191100871T
Other languages
English (en)
Inventor
Alessandro Moretta
Mariella Della Chiesa
Pascale Andre
Laurent Gauthier
François Romagne
Peter Andreas Nicolai Reumert Wagtmann
Ivan Svendsen
Stefan Zahn
Matthias Thorolfsson
Soren Berg Padkaer
Pieter Spee
Michael Wilken
Anders Svensson
Kristian Kjaergaard
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/002464 external-priority patent/WO2005003172A2/en
Priority claimed from EP05758642A external-priority patent/EP1791868B1/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY1122391T1 publication Critical patent/CY1122391T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B7/00—Special arrangements or measures in connection with doors or windows
    • E06B7/02—Special arrangements or measures in connection with doors or windows for providing ventilation, e.g. through double windows; Arrangement of ventilation roses
    • E06B7/08—Louvre doors, windows or grilles
    • E06B7/084—Louvre doors, windows or grilles with rotatable lamellae
    • E06B7/086—Louvre doors, windows or grilles with rotatable lamellae interconnected for concurrent movement
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0615—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the closing elements
    • E06B9/0638—Slats or panels
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0646—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position
    • E06B9/0653—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position stored side by side in the closing plane
    • E06B9/0661—Lazy tongue, pantograph or scissor-like systems in the plane of the opening
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/24—Screens or other constructions affording protection against light, especially against sunshine; Similar screens for privacy or appearance; Slat blinds
    • E06B9/26—Lamellar or like blinds, e.g. venetian blinds
    • E06B9/28—Lamellar or like blinds, e.g. venetian blinds with horizontal lamellae, e.g. non-liftable
    • E06B9/30—Lamellar or like blinds, e.g. venetian blinds with horizontal lamellae, e.g. non-liftable liftable
    • E06B9/302—Lamellar or like blinds, e.g. venetian blinds with horizontal lamellae, e.g. non-liftable liftable without ladder-tape, e.g. with lazy-tongs, with screw spindle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0646—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position
    • E06B9/0653—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position stored side by side in the closing plane
    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/06—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type
    • E06B9/0607—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position
    • E06B9/0646—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position
    • E06B9/0676—Shutters, movable grilles, or other safety closing devices, e.g. against burglary collapsible or foldable, e.g. of the bellows or lazy-tongs type comprising a plurality of similar rigid closing elements movable to a storage position characterised by the relative arrangement of the closing elements in the stored position stored in a stacked configuration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Civil Engineering (AREA)
  • Architecture (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Blinds (AREA)

Abstract

Περιγράφονται συνθέσεις και μέθοδοι για ρύθμιση ανοσοαπόκρισης σε υποκείμενο. Πιο συγκεκριμένα, περιγράφονται ανθρώπινα αντισώματα που ρυθμίζουν τη δραστικότητα ΝΚ κυττάρων και επιτρέπουν ενίσχυση της κυτταροτοξικότητας ΝΚ κυττάρου σε υποκείμενα θηλαστικά και αντισώματα που έχουν ιδιότητες σύνδεσης-αντιγόνου παρόμοιες προς αυτές του ανθρώπινου μονοκλωνικού αντισώματος 1-7F9 ή 14F1. Επίσης περιγράφονται θραύσματα και παράγωγα τέτοιων αντισωμάτων, καθώς και φαρμακευτικές συνθέσεις που περιλαμβάνουν τα ίδια και χρήσεις αυτών, συγκεκριμένα για χρήση σε θεραπεία, για αύξηση της δραστικότητας ή της κυτταροτοξικότητας ΝΚ κυττάρου σε υποκείμενα.
CY20191100871T 2004-07-01 2019-08-13 Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια CY1122391T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2004/002464 WO2005003172A2 (en) 2003-07-02 2004-07-01 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
PCT/DK2004/000470 WO2005003168A2 (en) 2003-07-02 2004-07-01 Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
DKPA200500025 2005-01-06
EP05758642A EP1791868B1 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
PCT/EP2005/053122 WO2006003179A2 (en) 2004-07-01 2005-07-01 Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use

Publications (1)

Publication Number Publication Date
CY1122391T1 true CY1122391T1 (el) 2021-01-27

Family

ID=38462469

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100871T CY1122391T1 (el) 2004-07-01 2019-08-13 Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια

Country Status (19)

Country Link
EP (1) EP1841941A1 (el)
JP (1) JP5770142B2 (el)
KR (1) KR101299167B1 (el)
CN (1) CN103509111A (el)
AT (1) ATE499386T1 (el)
BR (1) BRPI0512911B1 (el)
CY (1) CY1122391T1 (el)
DE (1) DE602005026538D1 (el)
DK (1) DK1791868T3 (el)
ES (2) ES2360467T3 (el)
HU (1) HUE045639T2 (el)
IL (1) IL179635A0 (el)
LT (1) LT2287195T (el)
MX (1) MX2007000210A (el)
NO (2) NO341198B1 (el)
PT (2) PT2287195T (el)
RU (1) RU2410396C2 (el)
TW (2) TWI472338B (el)
ZA (1) ZA200700736B (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3579879A4 (en) * 2017-02-09 2020-12-16 Memorial Sloan Kettering Cancer Center ANTI-BODY ANTI-KIR3DL1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1125130B1 (de) * 1998-10-29 2006-07-26 DakoCytomation Denmark A/S Nachweis von säure-resistenten mikroorganismen im stuhl
KR101325023B1 (ko) * 2003-07-02 2013-11-04 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
DK2287195T3 (da) * 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi

Also Published As

Publication number Publication date
IL179635A0 (en) 2007-05-15
BRPI0512911A (pt) 2008-04-15
KR101299167B1 (ko) 2013-08-30
RU2006144820A (ru) 2008-09-10
BRPI0512911B1 (pt) 2023-05-16
PT1791868E (pt) 2011-05-02
MX2007000210A (es) 2007-08-02
NO341198B1 (no) 2017-09-11
CN103509111A (zh) 2014-01-15
JP5770142B2 (ja) 2015-08-26
JP2013009676A (ja) 2013-01-17
DK1791868T3 (da) 2011-05-16
ES2738578T3 (es) 2020-01-23
RU2410396C2 (ru) 2011-01-27
ATE499386T1 (de) 2011-03-15
KR20070034568A (ko) 2007-03-28
TWI472338B (zh) 2015-02-11
EP1841941A1 (en) 2007-10-10
TWI422389B (zh) 2014-01-11
DE602005026538D1 (de) 2011-04-07
HUE045639T2 (hu) 2020-01-28
TW200612986A (en) 2006-05-01
NO20171133A1 (no) 2007-01-31
ZA200700736B (en) 2008-04-30
NO344566B1 (no) 2020-02-03
ES2360467T3 (es) 2011-06-06
NO20070585L (no) 2007-01-31
LT2287195T (lt) 2019-07-25
TW201235048A (en) 2012-09-01
PT2287195T (pt) 2019-07-29

Similar Documents

Publication Publication Date Title
WO2006003179A3 (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
MX2022002018A (es) Anticuerpos de union a cd3.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
MX2018016404A (es) Anticuerpos de union a cd3.
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
NO20070854L (no) Humane monoklonale antistoffer mot humant IL-4.
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
JP2013501814A5 (el)
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MY162984A (en) Humanized m-csf mice
EA201300016A1 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами
MX2022008582A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
BR112013031943A2 (pt) "proteínas e anticorpos contra g-csfr, composição que os compreendem e uso dos mesmos".
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
EA202091974A1 (ru) Связывающие bcma антитела и их применение
CY1122391T1 (el) Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια
EA201490549A1 (ru) Применение белка c-met для прогнозирования эффективности антител к фактору роста гепатоцитов (фрг) у пациентов с раком пищевода и желудка
WO2021087368A3 (en) Anti-cd45 antibodies and conjugates thereof
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
WO2022212654A3 (en) Cross-reactive monoclonal antibodies against coronaviruses
TH92681A (th) สารองค์ประกอบเภสัชภัณฑ์สารปฏิปักษ์แอนติบอดีชนิดต้าน cd40